Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC.

Sreekumar R, Emaduddin M, Al-Saihati H, Moutasim K, Chan J, Spampinato M, Bhome R, Yuen HM, Mescoli C, Vitale A, Cillo U, Rugge M, Primrose J, Hilal MA, Thirdborough S, Tulchinsky E, Thomas G, Mirnezami A, Sayan AE.

Cell Death Dis. 2019 Sep 23;10(10):703. doi: 10.1038/s41419-019-1885-6.

2.

Population-based observational study of acute pancreatitis in southern England.

PanWessex Study Group; Wessex Surgical Trainee Research Collaborative, Mirnezami A, Knight B, Moran B, Noble F, Branagan G, Primrose J, Pearson K, West M, Curtis N, Pucher P, Cuttress R, Pugh S, Underwood T.

Ann R Coll Surg Engl. 2019 Sep;101(7):487-494. doi: 10.1308/rcsann.2019.0055. Epub 2019 Jul 30.

PMID:
31362520
3.

Immuno-oncology for surgeons.

Lee SL, Al-Shamkhani A, Mirnezami A.

Br J Surg. 2019 Sep;106(10):1273-1282. doi: 10.1002/bjs.11224. Epub 2019 Jul 18. Review.

PMID:
31318438
4.

Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis.

Grisard E, Coan M, Cesaratto L, Rigo I, Zandonà L, Paulitti A, Andreuzzi E, Rampioni Vinciguerra GL, Poletto E, Del Ben F, Brisotto G, Biscontin E, Turetta M, Dassi E, Mirnezami A, Canzonieri V, Vecchione A, Baldassarre G, Mongiat M, Spizzo R, Nicoloso MS.

EBioMedicine. 2019 Aug;46:79-93. doi: 10.1016/j.ebiom.2019.06.044. Epub 2019 Jul 11.

5.

Transglutaminase-2 Mediates the Biomechanical Properties of the Colorectal Cancer Tissue Microenvironment that Contribute to Disease Progression.

Delaine-Smith R, Wright N, Hanley C, Hanwell R, Bhome R, Bullock M, Drifka C, Eliceiri K, Thomas G, Knight M, Mirnezami A, Peake N.

Cancers (Basel). 2019 May 21;11(5). pii: E701. doi: 10.3390/cancers11050701.

6.

Network Mapping of Molecular Biomarkers Influencing Radiation Response in Rectal Cancer.

Poynter L, Galea D, Veselkov K, Mirnezami A, Kinross J, Nicholson J, Takáts Z, Darzi A, Mirnezami R.

Clin Colorectal Cancer. 2019 Jun;18(2):e210-e222. doi: 10.1016/j.clcc.2019.01.004. Epub 2019 Feb 10. Review.

7.

Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.

Banerjee A, Birts CN, Darley M, Parker R, Mirnezami AH, West J, Cutress RI, Beers SA, Rose-Zerilli MJJ, Blaydes JP.

Carcinogenesis. 2019 Jul 20;40(7):871-882. doi: 10.1093/carcin/bgy174.

PMID:
30668646
8.

Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.

Sreekumar R, Harris S, Moutasim K, DeMateos R, Patel A, Emo K, White S, Yagci T, Tulchinsky E, Thomas G, Primrose JN, Sayan AE, Mirnezami AH.

JAMA Netw Open. 2018 Oct 5;1(6):e183115. doi: 10.1001/jamanetworkopen.2018.3115.

9.

Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data.

Chand M, Keller DS, Mirnezami R, Bullock M, Bhangu A, Moran B, Tekkis PP, Brown G, Mirnezami A, Berho M.

World J Gastrointest Oncol. 2018 Jul 15;10(7):145-158. doi: 10.4251/wjgo.v10.i7.145. Review.

10.

Bilateral versus unilateral botulinum toxin injections for chronic anal fissure: a randomised trial.

Pilkington SA, Bhome R, Welch RE, Ku F, Warden C, Harris S, Hicks J, Richardson C, Dudding TC, Knight JS, King AT, Mirnezami AH, Beck NE, Nichols PH, Nugent KP.

Tech Coloproctol. 2018 Jul;22(7):545-551. doi: 10.1007/s10151-018-1821-2. Epub 2018 Jul 18.

11.

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.

Pengelly RJ, Rowaiye B, Pickard K, Moran B, Dayal S, Tapper W, Mirnezami A, Cecil T, Mohamed F, Carr N, Ennis S.

J Mol Diagn. 2018 Sep;20(5):635-642. doi: 10.1016/j.jmoldx.2018.05.002. Epub 2018 Jun 22.

12.

Session 2: What causes liver metastases - lymph nodes or is it something else?

Siddiqui M, Nagtegaal I, Santiago I, Knijn N, Berho M, Mirnezami A, Rao S, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:39-42. doi: 10.1111/codi.14077. Review.

PMID:
29878686
13.

Session 2: Mutational discordance: the big challenge in personalized treatments - any solutions?

Siddiqui M, Chand M, Eng C, Mehdizadeh A, Mirnezami A, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:49-51. doi: 10.1111/codi.14079. Review.

PMID:
29878676
14.

The Colorectal Cancer Microenvironment: Strategies for Studying the Role of Cancer-Associated Fibroblasts.

Bhome R, Mellone M, Emo K, Thomas GJ, Sayan AE, Mirnezami AH.

Methods Mol Biol. 2018;1765:87-98. doi: 10.1007/978-1-4939-7765-9_6.

15.

Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk.

Del Vecchio F, Lee GH, Hawezi J, Bhome R, Pugh S, Sayan E, Thomas G, Packham G, Primrose J, Pichler M, Mirnezami A, Calin G, Bullock M.

Cancer Lett. 2018 May 1;421:94-102. doi: 10.1016/j.canlet.2018.02.022. Epub 2018 Feb 17.

PMID:
29458141
16.

Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer.

Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE, Mirnezami AH.

Cancer Lett. 2018 Apr 28;420:228-235. doi: 10.1016/j.canlet.2018.02.002. Epub 2018 Feb 7. Review.

17.

Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.

Bhome R, Goh RW, Bullock MD, Pillar N, Thirdborough SM, Mellone M, Mirnezami R, Galea D, Veselkov K, Gu Q, Underwood TJ, Primrose JN, De Wever O, Shomron N, Sayan AE, Mirnezami AH.

Aging (Albany NY). 2017 Dec 28;9(12):2666-2694. doi: 10.18632/aging.101355.

18.

Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.

Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M, Noble F, Moutasim KA, King EV, Vijayanand P, Mirnezami AH, Underwood TJ, Ottensmeier CH, Thomas GJ.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx121.

19.

A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.

Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G.

Trials. 2017 Aug 29;18(1):394. doi: 10.1186/s13063-017-2085-2.

20.

Pelvic exenteration with en bloc resection of the pelvic sidewall and intraoperative electron beam radiotherapy with Mobetron® for locally advanced rectal cancer.

Rangarajan K, Bhome R, Bateman N, Naga A, Simon M, Donovan K, Smith J, Mirnezami AH.

Tech Coloproctol. 2017 Jun;21(6):493-495. doi: 10.1007/s10151-017-1649-1. Epub 2017 Jun 14. No abstract available.

21.

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer.

West MA, Roman A, Sayan E, Primrose JN, Wedge SR, Underwood TJ, Mirnezami AH.

Crit Rev Oncol Hematol. 2017 Apr;112:80-102. doi: 10.1016/j.critrevonc.2017.02.008. Epub 2017 Feb 16. Review.

PMID:
28325268
22.

Profiling the MicroRNA Payload of Exosomes Derived from Ex Vivo Primary Colorectal Fibroblasts.

Bhome R, Goh R, Pickard K, Mellone M, Sayan AE, Mirnezami A.

Methods Mol Biol. 2017;1509:115-122.

23.

Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.

Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH.

New Horiz Transl Med. 2016 Jan;3(1):9-21.

24.

A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers.

Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, Manousopoulou A, Johnston HE, Hayden A, Thirdborough S, Liu Y, Smith DM, Mellows T, Kao WJ, Garbis SD, Mirnezami A, Underwood TJ, Eliceiri KW, Thomas GJ.

Oncotarget. 2016 Feb 2;7(5):6159-74. doi: 10.18632/oncotarget.6740.

25.

A top-down view of the tumor microenvironment: structure, cells and signaling.

Bhome R, Bullock MD, Al Saihati HA, Goh RW, Primrose JN, Sayan AE, Mirnezami AH.

Front Cell Dev Biol. 2015 May 29;3:33. doi: 10.3389/fcell.2015.00033. eCollection 2015. Review.

26.

miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.

Cellura D, Pickard K, Quaratino S, Parker H, Strefford JC, Thomas GJ, Mitter R, Mirnezami AH, Peake NJ.

Mol Cancer Res. 2015 Jul;13(7):1095-1105. doi: 10.1158/1541-7786.MCR-14-0466. Epub 2015 May 1.

27.

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.

Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose J, Packham G, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami A, Calin GA, Nicoloso MS.

Gut. 2016 Jun;65(6):977-989. doi: 10.1136/gutjnl-2015-309372. Epub 2015 Mar 24.

28.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH.

Oncotarget. 2015 Mar 30;6(9):7262-79.

29.

Systematic review of emergent laparoscopic colorectal surgery for benign and malignant disease.

Chand M, Siddiqui MR, Gupta A, Rasheed S, Tekkis P, Parvaiz A, Mirnezami AH, Qureshi T.

World J Gastroenterol. 2014 Dec 7;20(45):16956-63. doi: 10.3748/wjg.v20.i45.16956.

30.

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.

Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH.

World J Gastroenterol. 2014 Oct 14;20(38):14018-32. doi: 10.3748/wjg.v20.i38.14018. Review.

31.

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.

Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH.

Br J Cancer. 2014 Oct 14;111(8):1500-8. doi: 10.1038/bjc.2014.419. Epub 2014 Sep 16.

32.

Molecular profiling of the invasive tumor microenvironment in a 3-dimensional model of colorectal cancer cells and ex vivo fibroblasts.

Bullock MD, Mellone M, Pickard KM, Sayan AE, Mitter R, Primrose JN, Packham GK, Thomas G, Mirnezami AH.

J Vis Exp. 2014 Apr 29;(86). doi: 10.3791/51475.

33.

miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH.

Cancer Res. 2013 Nov 1;73(21):6435-47. doi: 10.1158/0008-5472.CAN-12-3308. Epub 2013 Aug 15.

34.

FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role.

Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, Primrose JN, Ottensmeier C, Packham GK, Thomas G, Mirnezami AH.

Br J Cancer. 2013 Jul 23;109(2):387-94. doi: 10.1038/bjc.2013.355. Epub 2013 Jul 4.

35.

Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.

Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, Mitter R, Primrose JN, Thomas GJ, Packham GK, Mirnezami AH.

Cell Death Dis. 2013 Jun 20;4:e684. doi: 10.1038/cddis.2013.213. Erratum in: Cell Death Dis. 2013;4:e748. Mirenzami, AH [corrected to Mirnezami, AH].

36.

New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?

Boncheva V, Bonney SA, Brooks SE, Tangney M, O'Sullivan G, Mirnezami A, Guinn BA.

Cancer Gene Ther. 2013 Mar;20(3):157-68. doi: 10.1038/cgt.2013.5. Epub 2013 Mar 15. Review.

PMID:
23492821
37.

Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications.

Mirnezami R, Chang GJ, Das P, Chandrakumaran K, Tekkis P, Darzi A, Mirnezami AH.

Surg Oncol. 2013 Mar;22(1):22-35. doi: 10.1016/j.suronc.2012.11.001. Epub 2012 Dec 25. Review.

38.

Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy.

Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R.

Surg Oncol. 2012 Dec;21(4):316-23. doi: 10.1016/j.suronc.2012.08.003. Epub 2012 Sep 14. Review.

PMID:
22981546
39.

A prospective case-control study of extralevator abdominoperineal excision (ELAPE) of the rectum versus conventional laparoscopic and open abdominoperineal excision: comparative analysis of short-term outcomes and quality of life.

Vaughan-Shaw PG, Cheung T, Knight JS, Nichols PH, Pilkington SA, Mirnezami AH.

Tech Coloproctol. 2012 Oct;16(5):355-62. doi: 10.1007/s10151-012-0851-4. Epub 2012 Jul 10.

PMID:
22777690
40.

The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.

Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH.

Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Review.

PMID:
22721580
41.

Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases.

Carr NJ, Finch J, Ilesley IC, Chandrakumaran K, Mohamed F, Mirnezami A, Cecil T, Moran B.

J Clin Pathol. 2012 Oct;65(10):919-23. Epub 2012 Jun 20.

PMID:
22718846
42.

MicroRNA Control of Invasion and Metastasis Pathways.

Sreekumar R, Sayan BS, Mirnezami AH, Sayan AE.

Front Genet. 2011 Sep 5;2:58. doi: 10.3389/fgene.2011.00058. eCollection 2011.

43.

MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression.

Bullock MD, Sayan AE, Packham GK, Mirnezami AH.

Biol Cell. 2012 Jan;104(1):3-12. doi: 10.1111/boc.201100115. Epub 2011 Dec 9. Review.

PMID:
22188537
44.

Acute radiation enteritis causing small bowel obstruction.

Curtis NJ, Bryant T, Raj S, Bateman AR, Mirnezami AH.

Ann R Coll Surg Engl. 2011 Oct;93(7):e129-30. doi: 10.1308/10.1308/147870811X602122.

45.

Early experience with laparoscopic extralevator abdominoperineal excision within an enhanced recovery setting: analysis of short-term outcomes and quality of life.

Vaughan-Shaw PG, King AT, Cheung T, Beck NE, Knight JS, Nichols PH, Nugent KP, Pilkington SA, Smallwood JA, Mirnezami AH.

Ann R Coll Surg Engl. 2011 Sep;93(6):451-9. doi: 10.1308/003588411X588621.

46.

Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis.

Mirnezami R, Mirnezami AH, Chandrakumaran K, Abu Hilal M, Pearce NW, Primrose JN, Sutcliffe RP.

HPB (Oxford). 2011 May;13(5):295-308. doi: 10.1111/j.1477-2574.2011.00295.x. Epub 2011 Mar 2. Review.

47.

Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis.

Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P.

Ann Surg. 2011 May;253(5):890-9. doi: 10.1097/SLA.0b013e3182128929. Review.

PMID:
21394013
48.

Clinical algorithms for the surgical management of locally recurrent rectal cancer.

Mirnezami AH, Sagar PM, Kavanagh D, Witherspoon P, Lee P, Winter D.

Dis Colon Rectum. 2010 Sep;53(9):1248-57. doi: 10.1007/DCR.0b013e3181e10b0e. Review.

PMID:
20706067
49.

Surgery for recurrent rectal cancer: technical notes and management of complications.

Mirnezami AH, Sagar PM.

Tech Coloproctol. 2010 Sep;14(3):209-16. doi: 10.1007/s10151-010-0585-0. Epub 2010 May 12. Review.

PMID:
20461538
50.

Laparoscopic resection for recurrent Crohn's disease: safety, feasibility and short-term outcomes.

Bandyopadhyay D, Sagar PM, Mirnezami A, Lengyel J, Morrison C, Gatt M.

Colorectal Dis. 2011 Feb;13(2):161-5. doi: 10.1111/j.1463-1318.2009.02100.x.

PMID:
19888954

Supplemental Content

Loading ...
Support Center